The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study

Aim: This study aims to investigate any modification of serological FSCN1 in prostate cancer patients compared with patients without neoplasia. Material & methods: Clinical data and blood specimens from patients with and without prostate cancer were obtained. A quantitative sandwich ELISA method was used to determine serological values of FSCN1. Results: Although serum values of FSCN1 were dissimilar in the two cohorts of patients (6.90 vs 7.33 ng/ml), the difference was not statistically significant (p = 0.20). Serum values of FSCN1 stratified for Gleason score groups were not significantly distinguishable (p = 0.65). A negative correlation (rho = -0.331; p = 0.009) was reported between FSCN1 and age. Conclusion: Further studies are required to evaluate a possible diagnostic role of FSCN1 in prostate cancer.

Download Full-text

The role of 5α‐reductase inhibitors in gastro‐oesophageal cancer risk: A nested case‐control study

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.4909 ◽

2019 ◽

Vol 29 (1) ◽

pp. 48-56

Author(s):

John Busby ◽

Reema Karasneh ◽

Peter Murchie ◽

Úna McMenamin ◽

Shahinaz M. Gadalla ◽

...

Keyword(s):

Cancer Risk ◽

Oesophageal Cancer ◽

Case Control Study ◽

Case Control ◽

Reductase Inhibitors ◽

Nested Case Control ◽

Control Study

Download Full-text

Estimation of Relative and Absolute Risks in a Competing-Risks Setting Using a Nested Case-Control Study Design: Example From the ProMort Study

American Journal of Epidemiology ◽

10.1093/aje/kwz026 ◽

2019 ◽

Vol 188 (6) ◽

pp. 1165-1173 ◽

Cited By ~ 1

Author(s):

Renata Zelic ◽

Daniela Zugna ◽

Matteo Bottai ◽

Ove Andrén ◽

Jonna Fridfeldt ◽

...

Keyword(s):

Prostate Cancer ◽

Competing Risks ◽

Case Control Study ◽

Case Control ◽

Likelihood Method ◽

Cancer Death ◽

Hazard Ratios ◽

Prostate Cancer Death ◽

Nested Case Control ◽

Control Study

Abstract In this paper, we describe the Prognostic Factors for Mortality in Prostate Cancer (ProMort) study and use it to demonstrate how the weighted likelihood method can be used in nested case-control studies to estimate both relative and absolute risks in the competing-risks setting. ProMort is a case-control study nested within the National Prostate Cancer Register (NPCR) of Sweden, comprising 1,710 men diagnosed with low- or intermediate-risk prostate cancer between 1998 and 2011 who died from prostate cancer (cases) and 1,710 matched controls. Cause-specific hazard ratios and cumulative incidence functions (CIFs) for prostate cancer death were estimated in ProMort using weighted flexible parametric models and compared with the corresponding estimates from the NPCR cohort. We further drew 1,500 random nested case-control subsamples of the NPCR cohort and quantified the bias in the hazard ratio and CIF estimates. Finally, we compared the ProMort estimates with those obtained by augmenting competing-risks cases and by augmenting both competing-risks cases and controls. The hazard ratios for prostate cancer death estimated in ProMort were comparable to those in the NPCR. The hazard ratios for dying from other causes were biased, which introduced bias in the CIFs estimated in the competing-risks setting. When augmenting both competing-risks cases and controls, the bias was reduced.

Download Full-text

Lung Cancer After Hodgkin’s Disease: A Nested Case-Control Study of the Relation to Treatment

Journal of Clinical Oncology ◽

10.1200/jco.2001.19.6.1610 ◽

2001 ◽

Vol 19 (6) ◽

pp. 1610-1618 ◽

Cited By ~ 99

Author(s):

A. J. Swerdlow ◽

M. J. Schoemaker ◽

R. Allerton ◽

A. Horwich ◽

J. A. Barber ◽

...

Keyword(s):

Lung Cancer ◽

Hodgkin's Disease ◽

Case Control Study ◽

Hodgkin’S Disease ◽

Case Control ◽

Lung Cancers ◽

Number Of Cycles ◽

Nested Case Control ◽

Control Study

PURPOSE: To investigate the causes of the raised risk of lung cancer in patients who have had Hodgkin’s disease, and in particular the relationship to treatment. PATIENTS AND METHODS: A nested case-control study was conducted within a cohort of 5,519 patients with Hodgkin’s disease treated in Britain during 1963 through 1993. For 88 cases of lung cancer and 176 matched control subjects, information on treatment and other risk factors was extracted from hospital case-notes, and odds ratios for lung cancer in relation to these factors were calculated. RESULTS: Risk of lung cancer was borderline significantly greater in patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy than those who did not receive this treatment (relative risk [RR] = 1.66; 95% confidence interval [CI], 0.99 to 2.82), and increased with number of cycles of MOPP (P = .07). Exclusion of lung cancers for which histologic confirmation was not available strengthened these associations (RR = 2.41; 95% CI, 1.33 to 4.51; P = .004 for any MOPP and P = .007 for trend with number of cycles of MOPP). Risks were not raised, however, after chlorambucil, vinblastine, procarbazine, and prednisone treatment. There was evidence that the raised risk of lung cancer occurring in relation to radiotherapy was restricted to histologies other than adenocarcinoma. CONCLUSION: The results suggest that MOPP chemotherapy may lead to elevated risk of lung cancer, at least in certain subgroups of patients. The role of chemotherapy in the etiology of lung cancer after Hodgkin’s disease deserves further investigation.

Download Full-text